Delving into the Latest Updates on Rise Biopharmaceuticals, Inc. with Synapse

Overview

This is a Phase I, multi center study to evaluate the safety and efficacy and determine the maximum tolerated dose (MTD) of RP72 as monotherapy and RP72 in combination with Gemcitabine in patients with pancreatic cancer.
The study has two arms:
Arm A: RP72 monotherapy
Arm B: RP72 in combination with Gemcitabine
Both treatment arms will follow a standard 3+3 design. Up to 48 adult patients with pancreatic cancer will be enrolled in this study.

Start Date19 Apr 2021

Sponsor / Collaborator

Rise Biopharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Rise Biopharmaceuticals, Inc.

Login to view more data

0 Patents (Medical) associated with Rise Biopharmaceuticals, Inc.

Login to view more data

100 Deals associated with Rise Biopharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Rise Biopharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data